Highlights
- Market Cap
- $327.67M
- Enterprise Value
- $323.86M
- EPS (TTM)
- -$1.44
- Gross Profit (TTM)
- -$2.68K
- EBITDA (TTM)
- -$19.52M
- Year Range
- $7.78 - $34.10
- ROA (TTM)
- -511.58%
- ROE (TTM)
- -891.35%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Greenwich LifeSciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Greenwich LifeSciences, Inc. (GLSI) has returned 14.33% so far this year and 151.78% over the past 12 months.
Greenwich LifeSciences, Inc.
- 1D
- 11.77%
- 1M
- -13.35%
- YTD
- 14.33%
- 6M
- 141.41%
- 1Y
- 151.78%
- 3Y*
- 20.32%
- 5Y*
- -7.10%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Sep 25, 2020, GLSI's average daily return is +0.81%, while the average monthly return is +11.01%. At this rate, your investment would double in approximately 0.6 years.
Historically, 42% of months were positive and 58% were negative. The best month was Dec 2020 with a return of +588.1%, while the worst month was Apr 2022 at -39.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.
On a daily basis, GLSI closed higher 47% of trading days. The best single day was Dec 9, 2020 with a return of +998.4%, while the worst single day was Apr 12, 2021 at -27.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 43.12% | -7.82% | -13.35% | 14.33% | |||||||||
| 2025 | 15.23% | -5.56% | -21.93% | 5.87% | -2.48% | -7.92% | 20.62% | 4.94% | -13.33% | -7.44% | -5.21% | 140.66% | 87.09% |
| 2024 | -17.87% | 40.74% | 63.98% | -37.71% | 19.40% | 16.39% | -6.60% | -13.03% | 2.50% | -6.40% | 5.95% | -21.19% | 6.75% |
| 2023 | 30.53% | -21.32% | -11.66% | -22.34% | 1.68% | -11.43% | -4.61% | -0.33% | -3.60% | -5.43% | 39.95% | -10.09% | -30.79% |
| 2022 | -24.09% | 5.52% | 0.67% | -39.60% | -34.68% | 9.43% | -4.49% | 17.18% | -4.01% | -0.99% | 54.83% | 8.96% | -37.53% |
| 2021 | 2.82% | -16.45% | 8.81% | 10.30% | -1.38% | 21.20% | -12.17% | 1.39% | -2.37% | -9.50% | -11.11% | -22.59% | -33.29% |
Benchmark Metrics
Greenwich LifeSciences, Inc. has an annualized alpha of 585.25%, beta of 0.74, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 28, 2020.
- This stock captured 246.68% of S&P 500 Index gains and 147.03% of its losses — amplifying both gains and losses, but participating more in upside than downside.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 585.25%
- Beta
- 0.74
- R²
- 0.00
- Upside Capture
- 246.68%
- Downside Capture
- 147.03%
Return for Risk
Risk / Return Rank
GLSI ranks 86 for risk / return — in the top 86% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Greenwich LifeSciences, Inc. (GLSI) and compare them to a chosen benchmark (S&P 500 Index).
| GLSI | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.74 | 0.90 | +0.84 |
Sortino ratioReturn per unit of downside risk | 2.54 | 1.39 | +1.16 |
Omega ratioGain probability vs. loss probability | 1.30 | 1.21 | +0.09 |
Calmar ratioReturn relative to maximum drawdown | 3.63 | 1.40 | +2.24 |
Martin ratioReturn relative to average drawdown | 7.95 | 6.61 | +1.35 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore GLSI risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Greenwich LifeSciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Greenwich LifeSciences, Inc. was 90.11%, occurring on Jun 16, 2022. The portfolio has not yet recovered.
The current Greenwich LifeSciences, Inc. drawdown is 66.74%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -90.11% | Dec 11, 2020 | 381 | Jun 16, 2022 | — | — | — |
| -30.5% | Sep 28, 2020 | 35 | Nov 13, 2020 | 4 | Nov 19, 2020 | 39 |
| -7.5% | Dec 7, 2020 | 2 | Dec 8, 2020 | 1 | Dec 9, 2020 | 3 |
| -3.83% | Nov 24, 2020 | 1 | Nov 24, 2020 | 5 | Dec 2, 2020 | 6 |
| -1.48% | Nov 20, 2020 | 1 | Nov 20, 2020 | 1 | Nov 23, 2020 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Greenwich LifeSciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Greenwich LifeSciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GLSI in comparison with other companies in the Biotechnology industry. Currently, GLSI has a P/B value of 150.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |